Roivant's New Respiratory-Focused Vant Adds Chronic Cough Candidate To The Portfolio
Respivant will be Roivant's 13th "vant," focused on developing what was Patara Pharma's mast cell stimulator for chronic cough in patients with idiopathic pulmonary fibrosis. Former Patara CEO Bill Gerhart will lead the firm.
You may also be interested in...
New data puts Merck & Co's P2X3 receptor antagonist ahead of the field but Bellus Health's rival in the class may benefit from issues over taste alteration with gefapixant.
The company emerged in 2017 with $135m to spin out rare genetic disease-focused subsidiaries. Now with 18 start-ups and two near-term filings for drug approvals, BridgeBio will fund existing programs as they progress and continue to buy new assets.
Termination of nelotanserin, a small molecule licensed from Arena, in Lewy body dementias comes after a dramatic shift toward gene therapy.